drugset / Trial / NCT01321008

Stage I/II Nasal NK Cell Lymphoma

NCT01321008

Phase 1/2 Terminated 1 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.

Timeline

Start
2011-05
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Prednisone Other / unclassified 100 mg Oral
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications